A newly published paper in PNAS details a research breakthrough that provides a promising starting point for scientists to create drugs that can cure C. diff—a virulent health care-associated ...

Affecting roughly half a million Americans each year, bacterial infections caused by Clostridioides difficile—commonly known as C. diff—are a serious and persistent problem for patients and hospitals ...

A novel combination of multiple advanced molecular imaging techniques has led to the discovery of two molecular structures, which could provide a therapeutic target for C. diff infections. “The most ...

The presence of antigen-specific and neutralizing antibodies was not associated with Clostridioides difficile infection symptoms, severity, therapy approach, treatment response, or recurrences in a ...

Researchers from the University of Maryland School of Medicine and their colleagues have identified the structure of the most lethal toxin produced by certain strains of Clostridium difficile bacteria ...

A toxoid vaccine candidate against Clostridioides difficile failed to reduce the incidence of infection in at-risk adults ages 50 and older, according to results of the phase III CLOVER trial. Of ...

A study published by PNAS explains breakthrough research around designing drugs that target C. diff bacterial infections that result in 15,000 deaths in the U.S. annually. The bacterium is potentially ...

A new imaging approach used microscopic glowing tags to reveal gene activity in individual C. diff cells in gut tissue samples from infected mice. Here, a resulting image shows a round cross-section ...

Clostridium difficile infection (CDI) is a common hospital-acquired infection that is associated with a high clinical and economic burden. Because of this management of CDI is quickly becoming a part ...